Five Antiretroviral Drug Class-Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection

J Int Assoc Provid AIDS Care. 2015 Sep-Oct;14(5):398-401. doi: 10.1177/2325957415596229. Epub 2015 Jul 17.

Abstract

Transmitted HIV-1 exhibiting reduced susceptibility to protease and reverse transcriptase inhibitors is well documented but limited for integrase inhibitors and enfuvirtide. We describe here a case of transmitted 5 drug class-resistance in an antiretroviral (ARV)-naïve patient who was successfully treated based on the optimized selection of an active ARV drug regimen. The value of baseline resistance testing to determine an optimal ARV treatment regimen is highlighted in this case report.

Keywords: enfuvirtide; integrase inhibitors; maraviroc; transmitted drug resistance; tropism.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Retroviral Agents / administration & dosage*
  • Cyclohexanes / administration & dosage
  • Drug Resistance, Viral
  • Enfuvirtide
  • HIV Envelope Protein gp41 / administration & dosage
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV Integrase Inhibitors / administration & dosage
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • Humans
  • Male
  • Maraviroc
  • Peptide Fragments / administration & dosage
  • Triazoles / administration & dosage
  • Viral Tropism

Substances

  • Anti-Retroviral Agents
  • Cyclohexanes
  • HIV Envelope Protein gp41
  • HIV Integrase Inhibitors
  • Peptide Fragments
  • Triazoles
  • Enfuvirtide
  • Maraviroc